Seek Returns

A vs. RDY: Agilent vs. Dr. Reddy's Laboratories Stock Comparison

How do Agilent (A) and Dr. Reddy's Laboratories (RDY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Agilent (A) and Dr. Reddy's Laboratories (RDY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while RDY is classified in Pharmaceuticals.

Agilent (A) trades as ordinary local shares, while Dr. Reddy's Laboratories (RDY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Agilent (A) and Dr. Reddy's Laboratories (RDY)
Profile ItemARDY
NameAgileThought, Inc. Class A Common StockDr. Reddy's Laboratories Ltd. ADR
Country/RegionUnited StatesIndia
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesPharmaceuticals
GICS Sub-IndustryLife Sciences Tools & ServicesPharmaceuticals
Market Capitalization49.28 billion USD12.43 billion USD
CurrencyUSDUSD
ExchangeNYSENYSE
Listing DateNovember 18, 1999April 11, 2001
Security TypeCommon StockADR

Price Performance

Cumulative Growth

A
RDY
GSPC
Loading price history…
Agilent (A) vs. Dr. Reddy's Laboratories (RDY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Agilent (A) and Dr. Reddy's Laboratories (RDY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Agilent (A) and Dr. Reddy's Laboratories (RDY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Agilent (A) and Dr. Reddy's Laboratories (RDY)
MetricARDY
Total Return (1Y)22.92%12.49%
Total Return (3Y, Annualized)19.33%5.76%
Total Return (5Y, Annualized)3.03%4.06%

Risk Profile

Drawdown History

A
RDY
GSPC
Loading price history…
Agilent (A) vs. Dr. Reddy's Laboratories (RDY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Agilent (A) and Dr. Reddy's Laboratories (RDY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Agilent (A) and Dr. Reddy's Laboratories (RDY)
MetricARDY
Volatility (1Y, Annualized)33.10%27.06%
Beta (5Y)1.220.30
Max Drawdown (5Y)-38.09%-32.01%
Avg. Volume (3M)2.25M2.89M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
A and RDY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Agilent (A) and Dr. Reddy's Laboratories (RDY)
MetricARDY
Sharpe Ratio (1Y)0.560.30
Sortino Ratio (1Y)0.960.43

Profitability

ROE (TTM)

Both Agilent (A) at 20.97% and Dr. Reddy's Laboratories (RDY) at 7.34% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.97%

Max
109.18%
A
20.97%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.34%

Max
109.18%
RDY
7.34%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Agilent (A) vs. Dr. Reddy's Laboratories (RDY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Agilent (A) at 19.53% keeps the most of each sales dollar — above its industry’s net margin range — and Dr. Reddy's Laboratories (RDY) at 8.49% also retains a top-quartile share.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.53%

A
19.53%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.49%

Max
18.05%
RDY
8.49%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Agilent (A) vs. Dr. Reddy's Laboratories (RDY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Agilent (A) at 25.56% operates in the top operating margin quartile, ahead of Dr. Reddy's Laboratories (RDY) at 14.73%, which runs around its industry’s norm.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.56%

Max
83.12%
A
25.56%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.73%

Max
83.12%
Q3
14.77%
RDY
14.73%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Agilent (A) vs. Dr. Reddy's Laboratories (RDY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Agilent (A) and Dr. Reddy's Laboratories (RDY)
MetricARDY
ROE (TTM)20.97%7.34%
ROA (TTM)8.63%3.37%
Net Margin (TTM)19.53%8.49%
Operating Margin (TTM)25.56%14.73%
Gross Margin (TTM)53.65%49.49%

Growth

Revenue Growth

Both Agilent (A) at 6.73% and Dr. Reddy's Laboratories (RDY) at 3.19% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Agilent (A) vs. Dr. Reddy's Laboratories (RDY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Agilent (A) at 3.16% and Dr. Reddy's Laboratories (RDY) at -24.14% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Agilent (A) vs. Dr. Reddy's Laboratories (RDY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Agilent (A) and Dr. Reddy's Laboratories (RDY)
MetricARDY
Revenue Growth (YoY)6.73%3.19%
Revenue Growth (3Y CAGR)0.48%10.96%
EPS Growth (YoY)3.16%-24.14%
EPS Growth (3Y CAGR)3.02%-1.72%

Financial Strength

Current Ratio (MRQ)

Both Agilent (A) at 2.05 and Dr. Reddy's Laboratories (RDY) at 1.93 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.05

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
A
2.05
Min
0.10

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.93

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
RDY
1.93
Min
0.10
Loading chart…
Agilent (A) vs. Dr. Reddy's Laboratories (RDY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Agilent (A) at 0.56 and Dr. Reddy's Laboratories (RDY) at 0.19 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.56

Max
1.42
Q3
0.65
A
0.56
Median
0.15
Q1
0.02
Min
0.00

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19

Max
1.42
Q3
0.65
RDY
0.19
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Agilent (A) vs. Dr. Reddy's Laboratories (RDY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Agilent (A) and Dr. Reddy's Laboratories (RDY)
MetricARDY
Current Ratio (MRQ)2.051.93
Debt / Equity (MRQ)0.560.19
Net Debt / EBITDA1.15-0.08

Dividends

Dividend Yield (TTM)

Both Agilent (A) at 0.59% and Dr. Reddy's Laboratories (RDY) at 55.06% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.59%

A
0.59%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

55.06%

RDY
55.06%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Agilent (A) vs. Dr. Reddy's Laboratories (RDY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Agilent (A) at 19.98% and Dr. Reddy's Laboratories (RDY) at 22.72% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.98%

A
19.98%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.72%

RDY
22.72%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Agilent (A) vs. Dr. Reddy's Laboratories (RDY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Agilent (A) and Dr. Reddy's Laboratories (RDY)
MetricARDY
Dividend Yield (TTM)0.59%55.06%
Dividend Payout Ratio (TTM)19.98%22.72%

Valuation

P/E Ratio (TTM)

Both Agilent (A) at 34.47 and Dr. Reddy's Laboratories (RDY) at 41.42 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.47

Max
85.34
Q3
43.46
A
34.47
Median
26.69
Q1
13.30
Min
0.07

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.42

Max
85.34
Q3
43.46
RDY
41.42
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Agilent (A) vs. Dr. Reddy's Laboratories (RDY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Dr. Reddy's Laboratories (RDY) at 0.04 sits in the cheaper P/S ratio quartile while Agilent (A) at 6.68 prices around its industry’s middle — RDY costs less per dollar of sales, though read it alongside growth and margins.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max
58.18
Q3
25.77
Median
7.30
A
6.68
Q1
3.01
Min
0.01

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.04

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
RDY
0.04
Min
0.01
Loading chart…
Agilent (A) vs. Dr. Reddy's Laboratories (RDY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Agilent (A) at 6.69 sits in the upper P/B ratio quartile, and Dr. Reddy's Laboratories (RDY) at 18.16 prices even higher, above its industry range.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max
13.53
A
6.69
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.16

RDY
18.16
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Agilent (A) vs. Dr. Reddy's Laboratories (RDY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Agilent (A) and Dr. Reddy's Laboratories (RDY)
MetricARDY
P/E Ratio (TTM)34.4741.42
P/S Ratio (TTM)6.680.04
P/B Ratio (MRQ)6.6918.16
Free Cash Flow Yield (TTM)2.15%-53.03%